Wechselwirkungen · Brilique
Brilique 90 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 53
HOS-123647 · Präparat HOS-095701
Medicinal products known to induce bradycardia Due to observations of mostly asymptomatic ventricular pauses and bradycardia, caution should be exercised when administering ticagrelor concomitantly with medicinal products known to induce bradycardia (see section 4.4). However, no evidence of clinically significant adverse reactions was observed in the PLATO trial after concomitant administration with one or more medicinal products known to induce bradycardia (e.g. 96% beta blockers, 33% calcium channel blockers diltiazem and verapamil and 4% digoxin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) digoxin (HOS-086172) calcium (HOS-085615) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:59:00Z · SHA-256 f815638059a70571d33a6ddc4107523f2ae567aafc2b20551ad4a9b0fb2f2aca · Passage 08775e08a1735636b5ecc4e1e461956865819e0e7cff7752c70400e86c68a1b0 · Zeichen 7248–7805 im Abschnitt